These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7819816)

  • 1. Use of single donor platelets.
    Kirkley SA; Blumberg N
    Blood Rev; 1994 Sep; 8(3):142-7. PubMed ID: 7819816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloimmunization as a problem for platelet transfusion.
    Bonacossa IA
    Transfus Med Rev; 1990 Apr; 4(2):144-8. PubMed ID: 2134622
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors.
    Vox Sang; 2003 Jan; 84(1):73-88. PubMed ID: 12542737
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
    McVey M; Cserti-Gazdewich CM
    Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention.
    Sigle JP; Thierbach J; Infanti L; Muriset M; Hunziker G; Chassot K; Niederhauser C; Gowland P; Holbro A; Sunic K; Buser A; Fontana S
    Vox Sang; 2013 Oct; 105(3):244-52. PubMed ID: 23773018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets as immunogens.
    Waters AH
    Vox Sang; 1994; 67 Suppl 3():125-7. PubMed ID: 7975474
    [No Abstract]   [Full Text] [Related]  

  • 8. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A specific assay for anti-HLA antibodies: application to platelet donor selection.
    Millard FE; Tani P; McMillan R
    Blood; 1987 Nov; 70(5):1495-9. PubMed ID: 3311206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
    Thiele T; Alt-Mayer T; Greinacher A; Bux J
    Vox Sang; 2016 Nov; 111(4):350-356. PubMed ID: 27432635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components.
    Xiao W; Tormey CA; Capetillo A; Maitta RW
    Vox Sang; 2013 Nov; 105(4):334-40. PubMed ID: 23802769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO and platelet transfusion therapy.
    Cooling L
    Immunohematology; 2007; 23(1):20-33. PubMed ID: 17425412
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet alloantigens--molecular, genetic, and clinical aspects.
    Mueller-Eckhardt C; Santoso S; Kiefel V
    Vox Sang; 1994; 67 Suppl 3():89-93. PubMed ID: 7975519
    [No Abstract]   [Full Text] [Related]  

  • 16. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
    Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
    Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets.
    O'Rafferty C; Rooney G; Hagan R; Woolfson M; O'Donghaile D; Fitzgerald J
    Transfus Med; 2017 Oct; 27 Suppl 5():369-374. PubMed ID: 28393455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy.
    De Clippel D; Baeten M; Torfs A; Emonds MP; Feys HB; Compernolle V; Vandekerckhove P
    Transfusion; 2014 Dec; 54(12):3036-42. PubMed ID: 24863861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.